Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline
Liliana B. Menalled et al.
am01-jan2011-issue12-en 

A randomized, placebocontrolled trial of latrepirdine in Huntington‘s disease
Karl Kieburtz et al.
am02-jan2011-issue12-en 

Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease
Doris C. V. Thu et al.
am03-jan2011-issue12-en 

Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY
Michael Orth and the European Huntington‘s Disease Network
am04-apr2011-issue13-en 

Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACKHD study: the 12-month longitudinal analysis
Sarah J. Tabrizi et al.
am05-apr2011-issue13-en 

Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington’s disease
John P. Miller et al.
am06-apr2011-issue13-en 

What is the impact of education on Huntington's disease?
Jose Luis López-Sendón et al.
am07-jul2011-issue14-en 

Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis
Charlotte Soneson et al.
am08-jul2011-issue14-en 

An antisense CAG repeat transcript at the JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington‘s diseaselike 2 mice
Brian Wilburn et al.
am09-jul2011-issue14-en 

Discrepancies in reporting the CAG repeat lengths for Huntington’s disease
Oliver Quarrell et al.
am10-jan2012-issue15-en 

Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity
Eran Tauber et al.
am11-jan2012-issue15-en 

A natural antisense transcript at the Huntington’s disease repeat locus regulates HTT expression
Daniel W. Chung et al.
am12-jan2012-issue15-en 

Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, doubleblind, placebo-controlled trial
Justo G. de Yébenes et al.
am01-jan2012-issue15-en